{ "company": "Thermo Fisher Scientific", "ticker": "TMO", "period": { "from": "2025-04-02", "to": "2026-04-02", "days": 365 }, "sentiment_breakdown": { "positive": 35, "negative": 17, "neutral": 66 }, "synthesis": { "executive_summary": "**Executive Summary: Thermo Fisher Scientific (TMO) Sentiment Analysis**\n\nThe sentiment analysis for Thermo Fisher Scientific (TMO) from April 2, 2025, to April 2, 2026, indicates a predominantly neutral market perception (55.9% of items), with positive sentiment significantly outweighing negative sentiment (29.7% positive vs. 14.4% negative). Key drivers of positive sentiment include strategic product innovation, highlighted by the launch of the Gibco CHOvantage GS Cell Line Development Kit, which is expected to accelerate biologics development and boost TMO's cell culture business. Additionally, strong financial performance, including exceeding Q4 earnings expectations, significant revenue growth, and a raised quarterly dividend, contributed to a bullish analyst consensus and sustained institutional investment.\n\nConversely, negative sentiment items, while fewer, were primarily associated with general medical research topics suchs as chronic disease management, post-COVID-19 health burdens, and cancer treatment advancements, largely sourced from academic publications. These items reflect broader health challenges rather than direct operational or financial concerns for TMO. Overall, the data suggests that Thermo Fisher Scientific's robust business performance, strategic product development, and positive financial indicators are fostering a favorable market outlook, despite a high volume of neutral information and general research-related negative sentiment.", "key_findings": [ "✓ TMO Stock May Gain From the Rollout of Gibco CHOvantage GS CLD Kit", "✓ Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).", "✓ Rockland Trust Co. Has $34.27 Million Holdings in Thermo Fisher Scientific Inc. $TMO", "✗ Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.", "✗ Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.", "✗ Integration of RNA Editing into Multiomics Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients." ], "overall_sentiment": "positive" }, "top_positive": [ { "title": "TMO Stock May Gain From the Rollout of Gibco CHOvantage GS CLD Kit", "date": "2026-04-02", "source": "alpha_vantage", "score": 0.527 }, { "title": "Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).", "date": "2026 Mar 1", "source": "pubmed", "score": 0.527 }, { "title": "Rockland Trust Co. Has $34.27 Million Holdings in Thermo Fisher Scientific Inc. $TMO", "date": "2026-04-01", "source": "alpha_vantage", "score": 0.511 }, { "title": "Thermo Fisher Scientific Stock: Leading Life Sciences Provider Faces Mixed Institutional Flows Amid Strong Fundamentals", "date": "2026-03-31", "source": "alpha_vantage", "score": 0.511 }, { "title": "Implementing Annotation Confidence Scoring in Untargeted Mass Spectrometry Workflows for Small Molecule Analysis.", "date": "2026 Apr 1", "source": "pubmed", "score": 0.511 }, { "title": "Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.", "date": "2026 Mar 1", "source": "pubmed", "score": 0.511 }, { "title": "Detection of Cytomegalovirus in Patients Attending a Tertiary Care Center: A Retrospective Analysis.", "date": "2026-04-02", "source": "pubmed", "score": 0.494 }, { "title": "Influence of computed tomography reconstruction algorithms on coronary artery calcium scores and reader agreement.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.494 }, { "title": "Electrochemical corrosion accompanies dendrite growth in solid electrolytes.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.494 }, { "title": "Reducing Hospital Readmissions for Injection Drug Use-Related Infections: A Rapid Qualitative Analysis of Health Care Teams' Consultations to Inform Intervention Design.", "date": "2026 Mar 1", "source": "pubmed", "score": 0.494 } ], "top_negative": [ { "title": "Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.", "date": "2026-04-02", "source": "pubmed", "score": -0.743 }, { "title": "Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.67 }, { "title": "Integration of RNA Editing into Multiomics Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.66 }, { "title": "Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated Review.", "date": "2026 Feb 2", "source": "pubmed", "score": -0.66 }, { "title": "Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.612 }, { "title": "Modelling lowering of raised blood pressure in pregnancy to reduce pre-eclampsia: secondary analysis of data from prospective cohort studies.", "date": "2026-04-02", "source": "pubmed", "score": -0.494 }, { "title": "Human CD3 complex is required for the generation of T-cell receptor-like chimeric antigen receptor targeting WT1 in natural killer cells.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.421 }, { "title": "Diagnostic performance of somatostatin receptor positron emission tomography in preoperative evaluation of pancreatic neuroendocrine tumor lymph node metastases.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.382 }, { "title": "Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification.", "date": "2026 Mar 3", "source": "pubmed", "score": -0.273 }, { "title": "Oral nutritional interventions in hospitalised older people at nutritional risk: a network meta-analysis of individual participant data.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.273 } ], "raw_data": { "total_items": 118, "items": [ { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Introduces the Gibco™ CTS™ Compleo™ Fill and Finish System to Help Streamline Cell Therapy Manufacturing", "url": "https://www.bakersfield.com/ap/news/thermo-fisher-scientific-introduces-the-gibco-cts-compleo-fill-and-finish-system-to-help-streamline/article_0d8eb5b7-b4d3-5ed2-88de-d8446b66188c.html", "date": "2026-04-02", "summary": "Thermo Fisher Scientific has launched the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated and functionally closed solution designed to streamline cell therapy manufacturing. This system addresses challenges in manual formulation and filling workflows, aiming to reduce risk, improve operational efficiency, and ensure product consistency. It is part of the larger Gibco™ Cell Therapy Systems™ portfolio, providing integrated solutions for Good Manufacturing Practice (GMP)-compliant, closed", "sentiment_score": 0.007988, "sentiment_label": "Neutral", "relevance_score": 0.315484, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Introduces the Gibco™ CTS™ Compleo™ Fill and Finish System to Help Streamline Cell Therapy Manufacturing", "url": "https://www.eagletribune.com/region/thermo-fisher-scientific-introduces-the-gibco-cts-compleo-fill-and-finish-system-to-help-streamline/article_75876a64-d09a-5510-9e97-c3f004937cf0.html", "date": "2026-04-02", "summary": "Thermo Fisher Scientific has launched the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated and functionally closed solution designed to streamline cell therapy manufacturing. This system addresses common challenges in manual formulation and filling by reducing manual intervention and improving consistency. Collaborators using the technology are already seeing benefits in advancing their cell therapy programs.", "sentiment_score": 0.46752, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Exosomes Market Evolution (2026) | Nano Vesicles, Liquid Biopsy, Oncology Research & Biotech Investments | Top Companies 2026 - Miltenyi Biotec, Novus Biologicals, Capital Biosciences, and Bio Techne", "url": "https://www.openpr.com/news/4452659/exosomes-market-evolution-2026-nano-vesicles-liquid", "date": "2026-04-02", "summary": "DataM Intelligence has released a new research report on the Exosomes Market, highlighting its projected growth between 2026 and 2033. The report offers in-depth insights into market dynamics, segmentation, and includes recent industry developments and mergers & acquisitions. Key players listed include Thermo Fisher Scientific Inc., Qiagen, Beckman Coulter, Inc., and Lonza, among others, with the market focusing on oncology, neurodegenerative diseases, and regenerative medicine applications.", "sentiment_score": 0.322957, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.833206, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "TMO Stock May Gain From the Rollout of Gibco CHOvantage GS CLD Kit", "url": "https://www.tradingview.com/news/zacks:4ee0b2097094b:0-tmo-stock-may-gain-from-the-rollout-of-gibco-chovantage-gs-cld-kit/", "date": "2026-04-02", "summary": "Thermo Fisher Scientific (TMO) has introduced its new Gibco CHOvantage GS Cell Line Development Kit, designed to accelerate biologics development and improve cell line productivity. This innovation is expected to boost TMO's cell culture business and stock performance, as the biologics market continues to expand due to increasing chronic diseases and demand for efficient therapeutic development. The company’s stock rose 0.6% after the announcement, and analysts predict a positive impact on its f", "sentiment_score": 0.522917, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "AAV Genome Sequencing Service Market Is Booming Rapidly with Strong Demand By 2033 | Thermo Fisher Scientific, Illumina, Danaher Corporation", "url": "https://www.openpr.com/news/4452449/aav-genome-sequencing-service-market-is-booming-rapidly-with", "date": "2026-04-02", "summary": "Coherent Market Insights has published a new research study on the Global \"AAV Genome Sequencing Service Market\" forecasting growth through 2033. The report segments the market by type, application, end-user, and region, identifying key players like Thermo Fisher Scientific, Illumina, and Danaher Corporation. It aims to provide a comprehensive analysis of market trends, drivers, restraints, competitive landscape, and regional dynamics to aid strategic decision-making.", "sentiment_score": 0.700842, "sentiment_label": "Bullish", "relevance_score": 0.817155, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader", "url": "https://www.biospace.com/press-releases/agilent-announces-the-biotek-cytation-9-cell-imaging-multimode-reader", "date": "2026-04-02", "summary": "Agilent Technologies has launched the BioTek Cytation 9 cell imaging multimode reader, enhancing its Cytation portfolio. This new instrument combines multimode microplate reading and high-content cell imaging, offering expanded capabilities and faster throughput for diverse research applications. Designed with customer feedback, it aims to accelerate discoveries in cell biology and drug development by streamlining workflows for both cell-based and biochemical assays.", "sentiment_score": 0.247193, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.699736, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Compagnie Lombard Odier SCmA Buys 5,895 Shares of Thermo Fisher Scientific Inc. $TMO", "url": "https://www.marketbeat.com/instant-alerts/filing-compagnie-lombard-odier-scma-buys-5895-shares-of-thermo-fisher-scientific-inc-tmo-2026-04-02/", "date": "2026-04-02", "summary": "Compagnie Lombard Odier SCmA increased its stake in Thermo Fisher Scientific Inc. by 2.0%, acquiring an additional 5,895 shares, bringing its total holdings to 299,655 shares valued at $173.64 million. Thermo Fisher Scientific recently reported strong quarterly results with $6.57 EPS and $12.22 billion in revenue, also raising its quarterly dividend. Despite some insider selling, analysts maintain a \"Moderate Buy\" rating with an average price target of $632.50.", "sentiment_score": 0.319232, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Exosome Research Market is Thriving Worldwide | Thermo Fisher Scientific, Illumina Inc, Miltenyi Biotec, QIAGEN", "url": "https://www.openpr.com/news/4452155/exosome-research-market-is-thriving-worldwide-thermo-fisher", "date": "2026-04-02", "summary": "The Exosome Research Market is projected to grow from USD 284.5 million in 2026 to USD 895.5 million by 2033, exhibiting a compound annual growth rate of 17.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report, by Coherent Market Insights, provides a detailed analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.", "sentiment_score": 0.401478, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Quantum-Si (NASDAQ: QSI) plans 2026 virtual meeting and pay vote", "url": "https://www.stocktitan.net/sec-filings/QSI/def-14a-quantum-si-inc-definitive-proxy-statement-d8c8792f6cd4.html", "date": "2026-04-01", "summary": "Quantum-Si (NASDAQ: QSI) will hold its fully virtual 2026 annual shareholder meeting on May 15, 2026, at 1:00 p.m. Eastern, where stockholders will vote on electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving a non-binding advisory say-on-pay for named executive officers. Founder Jonathan M. Rothberg, Ph.D., who beneficially owns all Class B shares, holds approximately 69.33% of the total voting power, effectively controlling the outcome of all proposals. The pr", "sentiment_score": 0.01343, "sentiment_label": "Neutral", "relevance_score": 0.621242, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares", "url": "https://www.stocktitan.net/sec-filings/DMAC/def-14a-dia-medica-therapeutics-inc-definitive-proxy-statement-e72e63605464.html", "date": "2026-04-01", "summary": "DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is proposing to expand its 2019 Omnibus Incentive Plan by adding 3.5 million shares, increasing the total authorized shares to 10.5 million, and extending the plan's term by ten years. This proposal will be voted on at the annual shareholder meeting on May 20, 2026, alongside the election of directors, ratification of Baker Tilly US, LLP as auditors, and an advisory vote on executive compensation. The company states the expansion is crucial for attracti", "sentiment_score": 0.126429, "sentiment_label": "Neutral", "relevance_score": 0.562159, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development", "url": "https://www.pharmiweb.com/press-release/2026-04-01/thermo-fisher-scientific-launches-integrated-platform-to-accelerate-biologics-development", "date": "2026-04-01", "summary": "Thermo Fisher Scientific has launched an integrated platform called the Gibco CHOvantage GS Cell Line Development Kit to speed up biologics development. This new platform aims to help manufacturers bring therapies to market faster, improve consistency, and control costs, especially for complex biologics and biosimilars. The kit offers high productivity, streamlined timelines, and royalty-free, clinical-stage licensing options to support scalable manufacturing.", "sentiment_score": 0.419322, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026", "url": "https://www.pharmiweb.com/press-release/2026-04-01/thermo-fisher-scientific-to-hold-earnings-conference-call-on-thursday-april-23-2026", "date": "2026-04-01", "summary": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced it will release its first-quarter 2026 financial results and hold a conference call on Thursday, April 23, 2026, at 8:30 a.m. ET. The call will discuss financial performance and future expectations, accessible via webcast on their website or by phone. A replay of the call will be available until July 22, 2026.", "sentiment_score": 0.010052, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Worldwide Factors Influencing the Rapid Evolution of the Life Science Tools Market", "url": "https://www.openpr.com/news/4451119/worldwide-factors-influencing-the-rapid-evolution-of-the-life", "date": "2026-04-01", "summary": "The life science tools market is projected to reach $379.95 billion by 2030, growing at a CAGR of 13.5%. This growth is fueled by automation, increased investments in genomics and proteomics, demand for personalized medicine, and advancements in clinical diagnostics and drug discovery. Key players like F. Hoffmann-La Roche Ltd. and Thermo Fisher Scientific Inc. are driving innovation, exemplified by strategic acquisitions and the development of advanced sequencing platforms such as Illumina's Mi", "sentiment_score": 0.332128, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.788698, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "SOLV SEC Filings - Solventum Corporation 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/SOLV/page-5.html", "date": "2026-04-01", "summary": "This page provides a comprehensive resource for investors to access Solventum Corporation's SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights various material events reported by Solventum, such as debt reduction strategies, asset sales, governance changes, and details related to 3M Company's ownership and share resales of SOLV stock. The platform offers AI-powered summaries and sentiment analysis for each filing to help users understand key financial and op", "sentiment_score": 0.189746, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.620969, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Key Factors and Emerging Trends Shaping the Lab Supplies Market Landscape", "url": "https://www.openpr.com/news/4451078/key-factors-and-emerging-trends-shaping-the-lab-supplies-market", "date": "2026-04-01", "summary": "The lab supplies market is set to reach $60.9 billion by 2030, growing at an 8.5% CAGR, driven by advancements in life sciences, diagnostics, and automation. Key trends include increased demand for premium consumables, automated equipment, and a focus on safety and sustainability. Leading companies like Thermo Fisher Scientific and Danaher Corporation are innovating to enhance accuracy and efficiency, with acquisitions like Calibre Scientific's purchase of Dynalab Corp. expanding market reach an", "sentiment_score": 0.340658, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.937937, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Smarter Raman QC for biopharma fill-finish with scalable model transfer", "url": "https://www.europeanpharmaceuticalreview.com/webinars/smarter-raman-qc-for-biopharma-fill-finish-with-scalable-model-transfer/1131205.article", "date": "2026-04-01", "summary": "This webinar, sponsored by Thermo Fisher Scientific and featuring Sudhir Dahal, explores how modern Raman spectroscopy can enhance biopharma fill-finish quality control. It focuses on leveraging faster analysis and multi-attribute insights, while addressing challenges like scalable model transfer across instruments and sites, managing fluorescence interference, and integrating data into Industry 4.0 environments for real-time release. The session offers practical strategies for implementing Rama", "sentiment_score": 0.015462, "sentiment_label": "Neutral", "relevance_score": 0.317277, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Live Cell Imaging Market Set to Boom Rapidly by 2033| Thermo Fisher Scientific Inc. • Merck KgaA • PerkinElmer Inc", "url": "https://www.openpr.com/news/4450996/live-cell-imaging-market-set-to-boom-rapidly-by-2033-thermo", "date": "2026-04-01", "summary": "The Live Cell Imaging market is expected to grow significantly, from US$ 1,924.4 Mn in 2025 to US$ 2,921.9 Mn by 2032, at a CAGR of 7.2%. This report provides an in-depth analysis of market dynamics, key players such as Thermo Fisher Scientific, Merck KgaA, and PerkinElmer Inc., regional trends, and growth opportunities with forecasts up to 2033. It serves as a strategic guide for stakeholders with competitive analysis, market segmentation, and crucial insights to foster sustainable growth.", "sentiment_score": 0.309732, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.978311, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Emerging Sub-Segments Transforming the Medical Device Subscription Market Landscape", "url": "https://www.openpr.com/news/4450971/emerging-sub-segments-transforming-the-medical-device", "date": "2026-04-01", "summary": "The medical device subscription market is projected to reach $24.89 billion by 2030, growing at a CAGR of 22.5%, driven by remote monitoring, AI, and telehealth integration. Key players like Thermo Fisher Scientific and Medtronic are shaping the industry, with innovations like next-generation health wearables fostering personalized wellness management. The market is segmented by device type, subscription model, application, and end-user, including diagnostic, therapeutic, and monitoring devices ", "sentiment_score": 0.343934, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.728688, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development", "url": "https://www.joplinglobe.com/region/national_business/thermo-fisher-scientific-launches-integrated-platform-to-accelerate-biologics-development/article_ad18a8e7-b52a-5823-9475-2517185e40af.html", "date": "2026-04-01", "summary": "Thermo Fisher Scientific has released an integrated cell line development platform, the Gibco™ CHOvantage™ GS Cell Line Development Kit, aimed at accelerating biologics development. This platform provides high productivity, streamlined timelines, and royalty-free, clinical-stage licensing options, addressing the growing demand for faster and more cost-effective manufacturing of protein therapeutics. The kit enables rapid generation of high-performing CHO cell lines and supports a seamless transi", "sentiment_score": 0.495984, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development", "url": "https://www.businesswire.com/news/home/20260401312925/en/Thermo-Fisher-Scientific-Launches-Integrated-Platform-to-Accelerate-Biologics-Development", "date": "2026-04-01", "summary": "Thermo Fisher Scientific has introduced a new integrated cell line development platform, the Gibco CHOvantage GS Cell Line Development Kit, designed to accelerate biologics development. This platform aims to reduce time to clinic, improve manufacturing efficiency, and lower costs for protein therapeutics and biosimilars. A key feature is its royalty-free, clinical-stage licensing, offering predictability and flexibility for manufacturers.", "sentiment_score": 0.429934, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development", "url": "https://www.voiceofalexandria.com/news/national_business_news/thermo-fisher-scientific-launches-integrated-platform-to-accelerate-biologics-development/article_1884e5bf-b53d-5ac9-a9ce-74457a7bb431.html", "date": "2026-04-01", "summary": "Thermo Fisher Scientific has launched a new integrated cell line development platform, the Gibco CHOvantage GS Cell Line Development Kit, designed to accelerate biologics development. This platform aims to help manufacturers bring therapies to market faster by improving productivity, streamlining timelines, and offering royalty-free clinical-stage licensing options. It integrates a transposon-based vector system with optimized media to enhance cell line productivity and process consistency from ", "sentiment_score": 0.43071, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Before markets open, Thermo Fisher posts Q1 results on April 23", "url": "https://www.stocktitan.net/news/TMO/thermo-fisher-scientific-to-hold-earnings-conference-call-on-upnbwmrdbbs3.html", "date": "2026-04-01", "summary": "Thermo Fisher Scientific Inc. (NYSE: TMO) announced it will release its first-quarter 2026 financial results before market open on Thursday, April 23, 2026. The company will hold a conference call at 8:30 a.m. ET on the same day to discuss its financial performance and future expectations. The call will be webcast live on the \"Investors\" section of their website, www.thermofisher.com.", "sentiment_score": 0.045882, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Key Factors and Emerging Trends Shaping the Life Science and Chemical Instrumentation Market Landscape", "url": "https://www.openpr.com/news/4450823/key-factors-and-emerging-trends-shaping-the-life-science", "date": "2026-04-01", "summary": "The life science and chemical instrumentation market is projected to reach $90.58 billion by 2030, driven by advanced omics technologies, personalized medicine research, and digital laboratories. Key trends include automated analytical instruments, high-throughput testing, and enhanced integration of laboratory information management systems, with major players like Agilent Technologies and Thermo Fisher Scientific leading innovation. Recent acquisitions, such as Spectris acquiring Micromeritics", "sentiment_score": 0.337807, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.674473, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Top Players and Market Competition in the In Situ Hybridization Industry", "url": "https://www.openpr.com/news/4450792/top-players-and-market-competition-in-the-in-situ-hybridization", "date": "2026-04-01", "summary": "The in situ hybridization market is projected to reach $3.08 billion by 2030, growing at an 11.3% CAGR, driven by personalized medicine, AI-driven analysis, and genomic research. Key players like Thermo Fisher Scientific and Danaher Corporation are shaping the industry, with a focus on innovations such as Hybridization Chain Reaction RNA Chromogenic in situ Hybridization (HCR RNA-CISH). The market is segmented by product types, techniques, probe types, applications, and end-users, highlighting i", "sentiment_score": 0.315331, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.850491, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Competitive Analysis: Key Market Leaders and New Entrants in the Lyme Disease Testing Industry", "url": "https://www.openpr.com/news/4450845/competitive-analysis-key-market-leaders-and-new-entrants-in", "date": "2026-04-01", "summary": "The Lyme disease testing market is projected to reach $16.46 billion by 2030, growing at a CAGR of 9.0%, driven by advancements in diagnostics and increased awareness of tick-borne illnesses. Key trends include AI-assisted tools, home-testing kits, and multi-disease panels. Companies like Roche, Thermo Fisher Scientific, and Quest Diagnostics are leading innovation, with strategic partnerships and technological advancements enhancing early and precise detection methods.", "sentiment_score": 0.309853, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.706562, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "Infectious Disease Diagnostics Testing Market Overview, Key Trends, and Major Player Analysis", "url": "https://www.openpr.com/news/4450512/infectious-disease-diagnostics-testing-market-overview-key", "date": "2026-04-01", "summary": "The infectious disease diagnostics testing market is projected to reach $65.49 billion by 2030, growing at a CAGR of 9.0%. This growth is driven by increasing global health challenges, demand for rapid diagnostic tools, and investments in healthcare. Key trends include stronger demand for early detection, wider adoption of point-of-care testing, and increased use of molecular diagnostics.", "sentiment_score": 0.442274, "sentiment_label": "Bullish", "relevance_score": 0.883281, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Smarter Raman QC for biopharma fill-finish with scalable model transfer", "url": "https://www.europeanpharmaceuticalreview.com/main-navigation/smarter-raman-qc-for-biopharma-fill-finish-with-scalable-model-transfer/1131205.article", "date": "2026-04-01", "summary": "This webinar, sponsored by Thermo Fisher Scientific and featuring Product Manager Sudhir Dahal, will explore how modern Raman spectroscopy can enhance biopharma fill-finish quality control. It will cover faster analysis, multi-attribute insight, and scalable model transfer, addressing challenges like model revalidation and fluorescence interference. Attendees will learn practical strategies for implementing Raman QC reliably across various instruments and sites.", "sentiment_score": 0.634825, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.459, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Rockland Trust Co. Has $34.27 Million Holdings in Thermo Fisher Scientific Inc. $TMO", "url": "https://www.marketbeat.com/instant-alerts/filing-rockland-trust-co-has-3427-million-holdings-in-thermo-fisher-scientific-inc-tmo-2026-04-01/", "date": "2026-04-01", "summary": "Rockland Trust Co. reduced its stake in Thermo Fisher Scientific Inc. by 7.6% in Q4, holding 59,133 shares valued at $34.27 million. Thermo Fisher Scientific recently exceeded Q4 earnings expectations with $6.57 EPS and $12.22 billion in revenue, raising its quarterly dividend to $0.47 per share. The stock maintains a \"Moderate Buy\" consensus rating with an average target price of $632.50, despite some insider selling by executives.", "sentiment_score": 0.342206, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Global Biostorage Service Market Size is Expected to Reach USD 655.81 Million by 2026", "url": "https://www.openpr.com/news/4450170/global-biostorage-service-market-size-is-expected-to-reach-usd", "date": "2026-04-01", "summary": "The global Biostorage Service market is projected to reach $1,658.22 million by 2033, growing from $655.81 million in 2026 with a CAGR of 14.17%. This growth is driven by advancements in precision medicine, biopharmaceutical R&D, and the expansion of new drug development. Key market players include Azenta, Thermo Fisher Scientific, and EPL Archives (VWR), with North America being the largest market.", "sentiment_score": 0.403668, "sentiment_label": "Bullish", "relevance_score": 0.927234, "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "VivoSim Announces Pricing of up to a $4 Million Public Offering", "url": "https://www.globenewswire.com/news-release/2026/04/01/3266585/37000/en/VivoSim-Announces-Pricing-of-up-to-a-4-Million-Public-Offering.html", "date": "2026-04-01", "summary": "VivoSim Labs, Inc. announced the pricing of a best-efforts public offering aiming to raise up to $4 million. An initial closing of $3 million is expected, involving the sale of common stock and pre-funded warrants, along with common warrants. A second closing for an additional $1 million is conditioned on certain market factors.", "sentiment_score": 0.118395, "sentiment_label": "Neutral", "relevance_score": 0.602374, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Takeda Pharmaceuticals To Layoff Nearly 250 Cambridge Employees", "url": "https://www.thecrimson.com/article/2026/4/1/takeda-pharmaceutical-layoffs/", "date": "2026-04-01", "summary": "Takeda Pharmaceutical Co. will lay off 247 employees at its Kendall Square location in Cambridge, Massachusetts, as part of a corporate restructuring approved by its board. An additional 387 employees in other states will also be affected. These cuts are aimed at streamlining corporate functions and redirecting resources towards the company’s late-stage drug pipeline, with an expected annual saving of over $1.25 billion by 2028.", "sentiment_score": 0.124554, "sentiment_label": "Neutral", "relevance_score": 0.605514, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher’s Glacios 3 Cryo TEM Puts AI At Center Of Growth", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fishers-glacios-3-cryo-tem-puts-ai-at-center-of-growt", "date": "2026-04-01", "summary": "Thermo Fisher Scientific recently unveiled its Glacios 3 Cryo-TEM, an advanced cryo electron microscope incorporating AI-supported tools and improved imaging clarity. This new system is designed to accelerate drug discovery and structural studies by reducing practical barriers to adoption. For investors, the launch represents a significant product milestone for the company, highlighting its focus on high-impact analytical tools and AI in drug development.", "sentiment_score": 0.328423, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Thermo Fisher (NYSE: TMO) director adds 66 Phantom Stock Units under deferred plan", "url": "https://www.stocktitan.net/sec-filings/TMO/form-4-thermo-fisher-scientific-inc-insider-trading-activity-89a30c7babed.html", "date": "2026-04-01", "summary": "Jennifer M. Johnson, a director at Thermo Fisher (TMO), was granted 66.02 Phantom Stock Units on March 28, 2026, under the company's Deferred Compensation Plan for Directors. These units, valued at $473.36 each, are convertible to common stock on a 1-for-1 basis, bringing her total holdings to 661.31 Phantom Stock Units. The shares will be distributed upon cessation of her director service or a change of control at the company.", "sentiment_score": 0.036902, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Qiagen N.V. Stock: Oversold Opportunity in Sample-to-Insight Leader Amid Biotech Sector Shifts", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-oversold-opportunity-in-sample-to-insight-leader-amid/69042402", "date": "2026-04-01", "summary": "Qiagen N.V. shares are trading near 52-week lows, presenting a potentially oversold opportunity for North American investors interested in the molecular diagnostics and life sciences sector. The company, a leader in Sample-to-Insight solutions, has received analyst upgrades and seen increased institutional interest despite recent market pressure. Its strategic focus on high-growth areas like next-generation sequencing and precision medicine, coupled with its strong balance sheet, positions it fo", "sentiment_score": 0.116265, "sentiment_label": "Neutral", "relevance_score": 0.624714, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Experiences Revision in Stock Evaluation Amid Market Volatility", "url": "https://www.marketsmojo.com/news/stocks-in-action/thermo-fisher-scientifics-technical-trend-shifts-from-sideways-to-mildly-bearish-amid-stock-decline-3927526", "date": "2026-04-01", "summary": "Thermo Fisher Scientific has seen a stock price adjustment to $473.36 from $488.85, reflecting significant volatility over the past year. Technical indicators show mixed signals, and its recent performance has lagged the S&P 500. However, the company has outperformed the S&P 500 over a ten-year period.", "sentiment_score": -0.248111, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher (NYSE: TMO) director receives 66 Phantom Stock Units as deferred pay", "url": "https://www.stocktitan.net/sec-filings/TMO/form-4-thermo-fisher-scientific-inc-insider-trading-activity-31369c6c2b56.html", "date": "2026-03-31", "summary": "Thermo Fisher Scientific director Keith R. Alexandra received 66 Phantom Stock Units as part of the company's Deferred Compensation Plan for Directors. These units, valued at $473.36 each, are convertible into common stock and distributed upon the cessation of his board service or a change of control. Following this transaction, Alexandra now holds a total of 1,270.44 Phantom Stock Units.", "sentiment_score": 0.014371, "sentiment_label": "Neutral", "relevance_score": 0.325078, "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "[Form 4] THERMO FISHER SCIENTIFIC INC. Insider Trading Activity", "url": "https://www.stocktitan.net/sec-filings/TMO/form-4-thermo-fisher-scientific-inc-insider-trading-activity-50493e4bc55a.html", "date": "2026-03-31", "summary": "This article details an insider trading activity by Scott M. Sperling, a director at Thermo Fisher Scientific Inc. (TMO). He reported the acquisition of 89.780 Phantom Stock Units, credited to his deferred compensation account at $473.36 per unit, bringing his total holdings to 17,591.800 units. These units are convertible to common stock and will be distributed upon cessation of his board service or a change of control.", "sentiment_score": 0.013148, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher (NYSE: TMO) director adds phantom stock units grant", "url": "https://www.stocktitan.net/sec-filings/TMO/form-4-thermo-fisher-scientific-inc-insider-trading-activity-4bf3569cef80.html", "date": "2026-03-31", "summary": "Thermo Fisher Scientific director Dion J. Weisler was granted 79.2200 phantom stock units on March 28, 2026, as part of his deferred director retainer. These units, valued at $473.36 each, are convertible to common stock on a 1-for-1 basis and increase his total to 2,717.8900 units. The shares will be distributed upon the cessation of his board service or a change of control.", "sentiment_score": 0.028881, "sentiment_label": "Neutral", "relevance_score": 0.312414, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Stock: Leading Life Sciences Provider Faces Mixed Institutional Flows Amid Strong Fundamentals", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/thermo-fisher-scientific-stock-leading-life-sciences-provider-faces-mixed/69041977", "date": "2026-03-31", "summary": "Thermo Fisher Scientific, a global leader in life sciences, reported strong quarterly results in January 2026, beating earnings expectations with significant revenue growth. Despite high institutional ownership and bullish analyst ratings, some investors have trimmed stakes, signaling caution. The company shows strong financials, dividend growth potential, and strategic developments, making it a key play for North American investors in healthcare innovation.", "sentiment_score": 0.496416, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Introduces Glacios 3 Cryo-TEM for Structural Biology Labs", "url": "https://www.labmanager.com/thermo-fisher-scientific-introduces-glacios-3-cryo-tem-for-structural-biology-labs-35171", "date": "2026-03-31", "summary": "Thermo Fisher Scientific has launched the Glacios 3 Cryo-TEM, a new 200 kV cryogenic transmission electron microscope designed to make advanced structural biology tools more accessible to laboratories. This instrument integrates AI-powered software and a flexible installation system, the READY System, to enhance throughput, data quality, and ease of use while reducing facility constraints. The Glacios 3 Cryo-TEM aims to empower more institutions and researchers to leverage cryo-EM for complex bi", "sentiment_score": 0.482303, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Abbott Oncology Integration Into OncoEMR Tests Long Term Growth Story", "url": "https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-oncology-integration-into-oncoemr-tests-long-term-gro", "date": "2026-03-31", "summary": "Abbott Laboratories is integrating its Precision Oncology portfolio into Flatiron Health's OncoEMR platform, aiming to simplify cancer diagnostics for clinicians across 1,600+ U.S. community cancer centers. This move follows Abbott's expansion into cancer diagnostics through its Exact Sciences deal and seeks to improve distribution and workflow integration of its oncology tests. Investors will need to watch clinician adoption and the overall impact on Abbott's long-term growth story, especially ", "sentiment_score": 0.018115, "sentiment_label": "Neutral", "relevance_score": 0.62831, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM", "url": "https://www.biospace.com/press-releases/thermo-fisher-scientific-launches-thermo-scientific-glacios-3-cryo-tem", "date": "2026-03-31", "summary": "Thermo Fisher Scientific has launched the Glacios 3 Cryo-TEM, a next-generation cryogenic transmission electron microscope designed to make structural biology research more accessible. Equipped with the READY System and AI-powered software, it aims to mitigate environmental disturbances, increase throughput, and improve data quality. This advancement will allow more institutions to utilize cryo-EM for tackling complex biological questions and accelerating therapeutic development.", "sentiment_score": 0.505522, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "SNP Genotyping and Analysis Market to See Booming Growth", "url": "https://www.openpr.com/news/4448851/snp-genotyping-and-analysis-market-to-see-booming-growth", "date": "2026-03-31", "summary": "The SNP Genotyping and Analysis Market is anticipated to experience significant growth from 2026 to 2033, driven by increasing industry demand and technological advancements. A new report by Coherent Market Insights offers a comprehensive analysis of market size, revenue trends, key growth factors, and competitive landscapes. The report aims to provide stakeholders with actionable insights for informed, data-driven decisions amidst global market dynamics.", "sentiment_score": 0.378127, "sentiment_label": "Bullish", "relevance_score": 0.710299, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM", "url": "https://www.joplinglobe.com/region/national_business/thermo-fisher-scientific-launches-thermo-scientific-glacios-3-cryo-tem/article_ad6ae885-39e7-5a7b-8b60-75ddf7864de6.html", "date": "2026-03-31", "summary": "Thermo Fisher Scientific has launched the Glacios 3 Cryo-TEM, a next-generation cryogenic transmission electron microscope designed to clarify structural biology and be more accessible to various lab environments. This advancement in 200 kV imaging aims to accelerate structure-based drug discovery and support research in areas like vaccine development and HIV. The Glacios 3 features improved ease-of-use, increased productivity, and enhanced connectivity for seamless sample transfer, enabling a b", "sentiment_score": 0.486786, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Large Scale Plasma Separation Market Is Going to Boom | Merck KGaA", "url": "https://www.openpr.com/news/4448685/large-scale-plasma-separation-market-is-going-to-boom-merck-kgaa", "date": "2026-03-31", "summary": "Coherent Market Insights has released a comprehensive report titled \"Large Scale Plasma Separation Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033\". The report analyzes market competition, geographic distribution, and growth potential, providing crucial insights for entrepreneurs, investors, researchers, and business strategists. It details industry performance, identifies key success factors, assesses risks, and projects economic analysis, ROI, and profit margi", "sentiment_score": 0.307921, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.715997, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM", "url": "https://www.businesswire.com/news/home/20260331831277/en/Thermo-Fisher-Scientific-Launches-Thermo-Scientific-Glacios-3-Cryo-TEM", "date": "2026-03-31", "summary": "Thermo Fisher Scientific has introduced the Glacios 3 Cryo-TEM, a next-generation cryogenic transmission electron microscope equipped with the READY System. This new instrument aims to make structural biology research more accessible by enabling installation in a broader range of lab environments and improving throughput and data quality through AI-powered software. It is expected to accelerate therapeutic development by allowing more institutions and researchers to utilize cryo-EM technology.", "sentiment_score": 0.438503, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM", "url": "https://finance.yahoo.com/sectors/healthcare/articles/thermo-fisher-scientific-launches-thermo-123000810.html", "date": "2026-03-31", "summary": "Thermo Fisher Scientific has launched the Thermo Scientific Glacios 3 Cryo-TEM, a next-generation cryogenic transmission electron microscope aimed at making advanced structural biology research more accessible. Equipped with the READY System, this new instrument mitigates environmental disturbances, allowing for installation in a broader range of lab environments and reducing renovation complexity. It features AI-powered software and improved ease-of-use to enhance throughput and data quality fo", "sentiment_score": 0.536092, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Thermo Fisher Scientific Inc. $TMO Stock Position Trimmed by James Hambro & Partners LLP", "url": "https://www.marketbeat.com/instant-alerts/filing-thermo-fisher-scientific-inc-tmo-stock-position-trimmed-by-james-hambro-partners-llp-2026-03-31/", "date": "2026-03-31", "summary": "James Hambro & Partners LLP reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% in the fourth quarter, now holding 241,339 shares valued at $139.9 million. Despite this trim, TMO remains the firm's 7th largest position, comprising approximately 5.0% of its portfolio. Analysts maintain a \"Moderate Buy\" consensus rating with an average target price of $632.50, and the company recently raised its quarterly dividend to $0.47 per share.", "sentiment_score": 0.011679, "sentiment_label": "Neutral", "relevance_score": 0.306173, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Northstar Advisory Group LLC Acquires Shares of 5,609 Thermo Fisher Scientific Inc. $TMO", "url": "https://www.marketbeat.com/instant-alerts/filing-northstar-advisory-group-llc-acquires-shares-of-5609-thermo-fisher-scientific-inc-tmo-2026-03-31/", "date": "2026-03-31", "summary": "Northstar Advisory Group LLC has acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO), purchasing 5,609 shares valued at approximately $3.25 million, making it the 28th largest holding in their portfolio. Institutional investors now own 89.23% of the company's stock, and analysts widely rate TMO as a \"Moderate Buy\" with a consensus target price of $632.50. This comes after Thermo Fisher Scientific recently exceeded quarterly earnings expectations and increased its quarterly divide", "sentiment_score": 0.441666, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Jefferies Adjusts Price Target on Merck & Co. to $138 From $132, Maintains Buy Rating", "url": "https://www.marketscreener.com/news/jefferies-adjusts-price-target-on-merck-co-to-138-from-132-maintains-buy-rating-ce7e51dedb8af02d", "date": "2026-03-31", "summary": "Jefferies has increased its price target for Merck & Co. (MRK) shares to $138 from $132, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article also provides a company profile for Merck & Co., detailing its business segments, geographical sales distribution, and analyst consensus.", "sentiment_score": -0.135857, "sentiment_label": "Neutral", "relevance_score": 0.588946, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-03-24", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774526000066/0000097745-26-000066-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "10-K", "title": "10-K - Annual report [Section 13 and 15(d), not S-K Item 405]", "date": "2026-02-26", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/0000097745-26-000018-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-02-12", "url": "https://www.sec.gov/Archives/edgar/data/97745/000114036126005014/0001140361-26-005014-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-01-29", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774526000012/0000097745-26-000012-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-01-12", "url": "https://www.sec.gov/Archives/edgar/data/97745/000114036126000871/0001140361-26-000871-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-12-01", "url": "https://www.sec.gov/Archives/edgar/data/97745/000114036125043790/0001140361-25-043790-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "10-Q", "title": "10-Q - Quarterly report [Sections 13 or 15(d)]", "date": "2025-10-31", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000159/0000097745-25-000159-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-10-29", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000156/0000097745-25-000156-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-10-22", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000150/0000097745-25-000150-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-10-07", "url": "https://www.sec.gov/Archives/edgar/data/97745/000114036125037501/0001140361-25-037501-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-09-02", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000111/0000097745-25-000111-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "10-Q", "title": "10-Q - Quarterly report [Sections 13 or 15(d)]", "date": "2025-08-01", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000101/0000097745-25-000101-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-07-23", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000095/0000097745-25-000095-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-07-23", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000093/0000097745-25-000093-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-05-28", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000069/0000097745-25-000069-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-05-22", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000066/0000097745-25-000066-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "10-Q", "title": "10-Q - Quarterly report [Sections 13 or 15(d)]", "date": "2025-05-02", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000041/0000097745-25-000041-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2025-04-23", "url": "https://www.sec.gov/Archives/edgar/data/97745/000009774525000034/0000097745-25-000034-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41923638", "title": "Learning multi-cellular representations of single-cell transcriptomics data enables characterization of patient-level disease states.", "authors": "Liu T et al.", "journal": "Cell systems", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41923638/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41920124", "title": "Revisiting age- and sex-dependent serum tryptase reference intervals: Is additional evidence needed to refine current estimates?", "authors": "Chantran Y et al.", "journal": "The Journal of allergy and clinical immunology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41920124/", "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41919739", "title": "Implementing Annotation Confidence Scoring in Untargeted Mass Spectrometry Workflows for Small Molecule Analysis.", "authors": "Krakko D et al.", "journal": "Analytical chemistry", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41919739/", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41918709", "title": "Modelling lowering of raised blood pressure in pregnancy to reduce pre-eclampsia: secondary analysis of data from prospective cohort studies.", "authors": "Wright A et al.", "journal": "BMJ medicine", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41918709/", "sentiment": { "label": "negative", "score": -0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41917668", "title": "Detection of tRNA-Derived Small RNAs in Arabidopsis thaliana via Northern Blotting: Exploring Potential Biomarkers for Phytohormone Analysis.", "authors": "Pujara DS et al.", "journal": "Methods in molecular biology (Clifton, N.J.)", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41917668/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41917520", "title": "Associations Between Different Eosinophil Activity Markers and Clinical Outcomes in Young Asthmatics.", "authors": "Jõgi NO et al.", "journal": "Clinical and translational allergy", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41917520/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41915787", "title": "An increased number of heterozygous calls in the AxiomTM Equine Genotyping Array.", "authors": "Gmel AI et al.", "journal": "G3 (Bethesda, Md.)", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41915787/", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41913862", "title": "Detection of Cytomegalovirus in Patients Attending a Tertiary Care Center: A Retrospective Analysis.", "authors": "Subbarayan Rajasekaran S et al.", "journal": "Cureus", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41913862/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41913717", "title": "Visualization of Multi-indication Randomized Control Trial Evidence to Support Decision Making in Oncology: A Case Study on Bevacizumab.", "authors": "Anwer S et al.", "journal": "Medical decision making : an international journal of the Society for Medical Decision Making", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41913717/", "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41912495", "title": "Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification.", "authors": "Andersen LS et al.", "journal": "Blood cancer journal", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41912495/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41910757", "title": "[Olanzapine long acting injectable in new application form-Hope for the absence of post-injection delirium/sedation syndromes].", "authors": "Paulzen M et al.", "journal": "Der Nervenarzt", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41910757/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41910519", "title": "Reply.", "authors": "Gattinger P et al.", "journal": "The Journal of allergy and clinical immunology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41910519/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41903301", "title": "Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).", "authors": "Kanemura H et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41903301/", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41903103", "title": "Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Thailand: Epidemiological Data Update.", "authors": "Thakkar K et al.", "journal": "Pulmonary therapy", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41903103/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41898871", "title": "Internal Validation of a Mitochondrial DNA Control Region Sequencing Workflow Using Precision ID mtDNA Whole Genome Panel, Ion Chef™ System and Ion S5™ XL System.", "authors": "Shue BH et al.", "journal": "Genes", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41898871/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41898311", "title": "Integration of RNA Editing into Multiomics Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients.", "authors": "Bernal YA et al.", "journal": "Biomedicines", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41898311/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41896400", "title": "Post-COVID-19 Burden of Severe Influenza in England Among Overall Population and High-Risk Groups: Results From the INFORM Study, 2022-2023.", "authors": "Meeraus W et al.", "journal": "Infectious diseases and therapy", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896400/", "sentiment": { "label": "negative", "score": -0.67, "confidence": 0.67 } }, { "source": "pubmed", "pmid": "41895568", "title": "Accumulation Patterns of Polychlorinated Alkanes in an Arctic Marine Food Web.", "authors": "Giebichenstein J et al.", "journal": "Environmental research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895568/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41893822", "title": "Correction: Boikos et al. Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review. Vaccines 2025, 13, 381.", "authors": "Boikos C et al.", "journal": "Vaccines", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41893822/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41887965", "title": "Influence of computed tomography reconstruction algorithms on coronary artery calcium scores and reader agreement.", "authors": "Yang LD et al.", "journal": "Journal of cardiovascular computed tomography", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41887965/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41887157", "title": "Corrigendum to \"Systemic distribution and transplacental transfer of micro- and nanoplastics in a filter-feeding marine predator\" [Environ. Res. Volume 298, 1 June 2026, 124237].", "authors": "Ruiz-Sagalés M et al.", "journal": "Environmental research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41887157/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41886673", "title": "Oral nutritional interventions in hospitalised older people at nutritional risk: a network meta-analysis of individual participant data.", "authors": "Kiesswetter E et al.", "journal": "The Cochrane database of systematic reviews", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41886673/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41884877", "title": "Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.", "authors": "Okamura M et al.", "journal": "Progress in rehabilitation medicine", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41884877/", "sentiment": { "label": "negative", "score": -0.743, "confidence": 0.74 } }, { "source": "pubmed", "pmid": "41883204", "title": "Delonix regia flower extract protects against diabetic cardiac remodeling via modulating eNOS/NO/cGMP and NF-κB/iNOS/TNF-α trajectories.", "authors": "Hassan N et al.", "journal": "The Journal of pharmacy and pharmacology", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41883204/", "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41882535", "title": "Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.", "authors": "Sartini C et al.", "journal": "BMC gastroenterology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882535/", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "pubmed", "pmid": "41882365", "title": "Electrochemical corrosion accompanies dendrite growth in solid electrolytes.", "authors": "Fincher CD et al.", "journal": "Nature", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882365/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41880124", "title": "Development of the Patient Satisfaction with Medication for Diabetes (PSMD) questionnaire.", "authors": "Boye KS et al.", "journal": "Journal of patient-reported outcomes", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41880124/", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41879365", "title": "Giant Magnetostriction in Ferrimagnetic SmFe(5)As(3).", "authors": "Karychort O et al.", "journal": "Angewandte Chemie (International ed. in English)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41879365/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41878748", "title": "Characteristics of Adult Severe Uncontrolled Asthma Patients in Primary Care and Modifications in Prescribed Inhalation Treatments.", "authors": "Konradsen JR et al.", "journal": "Journal of asthma and allergy", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41878748/", "sentiment": { "label": "negative", "score": -0.103, "confidence": 0.1 } }, { "source": "pubmed", "pmid": "41876063", "title": "Asthma Impairment and Risk Questionnaire predicts short- and long-term exacerbation occurrence across asthma severities.", "authors": "McCann WA et al.", "journal": "Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41876063/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41875590", "title": "Multi-laboratory development of bioanalytical methods for two cyclic peptides, cyclorasin9A5 and 3003pep.", "authors": "Ishikawa R et al.", "journal": "Journal of chromatography. B, Analytical technologies in the biomedical and life sciences", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41875590/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41870027", "title": "Automated Online Direct mRNA Sequence Mapping Using Partial RNase T1 Digests.", "authors": "Dale JS et al.", "journal": "Analytical chemistry", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870027/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41870025", "title": "Molecular Probes for Sulfatase Detection and Bio-Imaging.", "authors": "Cheekatla SR et al.", "journal": "Chembiochem : a European journal of chemical biology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870025/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41865189", "title": "Low-resolution FAIMS for increased peptide coverage in low-load and single-cell proteomics.", "authors": "Hoch DG et al.", "journal": "Scientific reports", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41865189/", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41864206", "title": "The E3-ome gene-centric compendium reveals the human E3 ligase landscape.", "authors": "Chua NK et al.", "journal": "Cell", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41864206/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41859043", "title": "Clinically aggressive early-onset pancreatic ductal adenocarcinoma with KRAS wild-type status: A case report.", "authors": "Avendaño ME et al.", "journal": "Biomedical reports", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41859043/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41857718", "title": "-Impact of first-trimester preeclampsia screening on perinatal and maternal morbidity: the RANSPRE open multicenter randomized trial.", "authors": "Tsatsaris V et al.", "journal": "BMC pregnancy and childbirth", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41857718/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41857682", "title": "Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.", "authors": "Musallam KM et al.", "journal": "European journal of haematology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41857682/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41852856", "title": "Dupilumab in patients with cold urticaria: Results from a phase 3 trial.", "authors": "Metz M et al.", "journal": "The journal of allergy and clinical immunology. Global", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41852856/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41850747", "title": "Comprehensive multi-platform tyrosine kinase profiling reveals novel actionable FGFR aberrations across sarcomas affecting the young.", "authors": "Fordham AM et al.", "journal": "Molecular cancer therapeutics", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41850747/", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41849846", "title": "Diagnostic performance of somatostatin receptor positron emission tomography in preoperative evaluation of pancreatic neuroendocrine tumor lymph node metastases.", "authors": "Gudmundsdottir H et al.", "journal": "Surgery", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41849846/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41847855", "title": "CD5L:p40, a novel heterodimeric regulator of type 2 inflammation.", "authors": "Wang C et al.", "journal": "Journal of immunology (Baltimore, Md. : 1950)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41847855/", "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "pubmed", "pmid": "41847154", "title": "Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.", "authors": "Takamori S et al.", "journal": "JTO clinical and research reports", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41847154/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41846680", "title": "Gestational age amplifies the risk of airflow obstruction in adult smokers with asthma.", "authors": "Konradsen JR et al.", "journal": "ERJ open research", "date": "2026-04-02", "url": "https://pubmed.ncbi.nlm.nih.gov/41846680/", "sentiment": { "label": "negative", "score": -0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41844540", "title": "Reducing Hospital Readmissions for Injection Drug Use-Related Infections: A Rapid Qualitative Analysis of Health Care Teams' Consultations to Inform Intervention Design.", "authors": "Key S et al.", "journal": "Journal of addiction medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41844540/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41843665", "title": "Nudibranch color diversity shares a common physical basis in guanine photonic structure 'pixels'.", "authors": "Humphrey S et al.", "journal": "Proceedings of the National Academy of Sciences of the United States of America", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41843665/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41843174", "title": "Human CD3 complex is required for the generation of T-cell receptor-like chimeric antigen receptor targeting WT1 in natural killer cells.", "authors": "Luanpitpong S et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843174/", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41843011", "title": "Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study.", "authors": "Kulthanan K et al.", "journal": "American journal of clinical dermatology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843011/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41827732", "title": "Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated Review.", "authors": "Delcuratolo MD et al.", "journal": "Cancers", "date": "2026 Feb 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41827732/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } } ] } }